Navigation Links
MedAvante Names Leading Expert to Head Neurocognition Therapeutic Area
Date:1/10/2011

HAMILTON, N.J., Jan. 10, 2011 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system (CNS) disorders, announced the appointment of Christopher Randolph, PhD, ABPP-CN, to the new position of Vice President, Neurocognition.  Dr. Randolph will lead a growing team of clinical and training experts and experienced, calibrated clinicians focusing on Alzheimer's disease (AD), mild cognitive impairment (MCI) and other neurocognitive disorders.

"MedAvante has made a serious commitment to helping drug developers in this vital therapeutic category reduce their risk of failure due to inconclusive trial results," said Paul M. Gilbert, Chief Executive Officer of MedAvante.  "Chris Randolph is a highly accomplished, widely recognized expert in Alzheimer's disease clinical trials, and he brings with him a wealth of domain expertise as well as a highly successful study track record."

"Having Chris Randolph join our senior scientific leadership team ideally complements MedAvante's science-driven methodologies that are bringing about a paradigm shift in the way CNS clinical trials are conducted," said Gilbert.  

Dr. Randolph is the author of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a brief neurocognitive battery used widely around the world.  He has consulted on test development for over 20 years, including the revisions of the Wechsler intelligence and memory scales.  His extensive experience in CNS clinical trials includes work as an investigator and consultant, as well as creating and supervising rater training programs for a large number of Phase 2 and Phase 3 multinational studies in AD, schizophrenia, stroke, hepatic encephalopathy, and traumatic brain injury.

"The landscape of CNS clinical trials has changed substantially over the last 10-15 years, particularly in Alzheimer's disease," said Dr. Randolph.  "Today's emphasis on early diagnosis, early intervention, and the identification of disease-modifying therapies requires re-thinking traditional approaches to designing and implementing clinical trial methodologies, from the choice of endpoints to screening procedures to reducing noise in clinical assessments."

"MedAvante has a proven track record of applying a scientifically rigorous and technologically advanced approach to solving these problems in psychiatry trials," said Dr. Randolph.  "I am extremely excited by the opportunity to bring these solutions to bear upon clinical trials in AD and other neurological illnesses."

Dr. Randolph is the author of numerous peer-reviewed articles, board-certified in clinical neuropsychology and continues to serve as Clinical Professor of Neurology and Director of the Neuropsychology service at Loyola University Medical Center in Maywood, Illinois.

About MedAvante, Inc.

MedAvante is the premier global provider of centralized expert psychiatric rating and monitoring services to the pharmaceutical, biotechnology and medical device industries. Its flagship service, MedAvante Centralized Ratings, provides real-time assessments, either by telephone or videoconference, of subjects in global drug trials. Centralizing the assessors and blinding them to study protocols results in a level of standardization, calibration and objectivity that is not achievable with a decentralized group of study raters participating from unconnected investigative sites. In addition to Centralized Ratings, the company provides Continuous Quality Control (CQC), a monitoring service in which expert calibrated trainers review site-based study interviews via audio and video.  MedAvante solutions help sponsors achieve increased drug effect and reduced trial failure rates, enabling them to bring better drugs to market faster. MedAvante operates facilities in Hamilton, NJ, Madison, WI, and Moscow, Russia.  For more information, please visit www.medavante.com.


'/>"/>
SOURCE MedAvante, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
2. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
3. MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimers Disease Trials
4. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
5. ICON and MedAvante Sign Alliance Agreement
6. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
7. West Names New President of Pharmaceutical Packaging Systems
8. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
9. NxStage Names Joseph Turk President, North America
10. Philips Names Recipients of Its 2010 Impact Awards
11. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Mass. , February 23, 2017 - ...   ... Honoring Rare Disease Day Open to All at http://www.shire.com/RareCount   ... today announced the launch of ,Rare Count, in honor of Rare ... diseases, which equates to nearly one in 20 global citizens. It ...
(Date:2/22/2017)... , Feb. 22, 2017 IRIDEX Corporation (Nasdaq: ... release financial results for the fourth quarter and 2016 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... deals and agreements entered into by the worlds leading ... Description The Global Spinal Cord Partnering Terms ... to partnering deals and agreements entered into by the ... partnering deals - Top deals by value ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing ... who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can ... they are free from the shame, stigma, and harmful labeling believed to ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, ... is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... of neurosurgeons in Michigan performing minimally invasive back surgery that often results in ...
(Date:2/22/2017)... ... , ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: ... 1:00 PM ET. A recording of the webinar will also be made available following ... you want to find out what really happened in the seniors housing and care ...
Breaking Medicine News(10 mins):